Clinical trials: Relapsed Ovarian Cancer
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Ovarian Cancer
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer.
- Trial name
- NCT03639246
- Testing
- AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD)
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- Aravive, Inc.
Ovarian Cancer, Fallopian Tube Cancer
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Multi-center, phase III trial of DCVAC/OvCa added to standard of care treatments for relapsed ovarian cancer. Patients will receive study treatment until all doses are administered, or other criteria are met.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- VITALIA (NCT03905902)
- Testing
- DCVAC/OvCa
- Sponsor
- SOTIO a.s.
Ovarian Cancer
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression
- Trial name
- NCT00408967
- Testing
- Tucotuzumab celmoleukin (EMD 273066)
- Sponsor
- EMD Serono
Recurrent Ovarian Carcinoma
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with…
- Trial name
- NCT03353831
- Testing
- Bevacizumab, Atezolizumab, Chemotherapy
- Where
- 111 sites in Austria, Belgium and 10 more
- Volunteers
- 574 people
- Sponsor
- AGO Research GmbH
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Trial name
- NCT00006812
- Testing
- capecitabine
- Where
- 31 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
This phase II trial is studying how well giving cisplatin together with flavopiridol works in treating patients with advanced ovarian epithelial cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer
- Trial name
- NCT00083122
- Testing
- cisplatin, alvocidib, cisplatin/flavopiridol
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer
A Study of Niraparib in Patients With Relapsed Ovarian Cancer
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens.
- Trial name
- NCT04392102
- Testing
- ZL-2306(Niraparib）
- Where
- 7 sites in China
- Volunteers
- 15 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00354601
- Testing
- capecitabine, docetaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Fallopian Tube Cancer, Ovarian Cancer
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002895
- Testing
- chemotherapy
- Where
- 21 sites in Austria, Belgium and 8 more
- Volunteers
- 1,400 people
- Sponsor
- Medical Research Council
Ovarian Neoplasms, Recurrent Ovarian Carcinoma
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.
- Conditions
- Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT04999605
- Testing
- AK112 low dose, AK112 medium dose, AK112 high dose
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Akeso
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with recurrent or…
- Trial name
- NCT00004037
- Testing
- docetaxel
- Where
- 67 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Cancer, Ovarian Cancer
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy.
- Trial name
- NCT00523380
- Testing
- recombinant interleukin-21, caelyx (pegylated liposomal doxorubicin)
- Where
- 7 sites in France, Germany
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002508
- Testing
- carboplatin, etoposide, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Temple University
Ovarian Cancer
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory epithelial ovarian cancer.
- Trial name
- NCT03916679
- Testing
- anti-MESO CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ovarian Cancer
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Compatibility of the topotecan therapy in combination with carboplatin.
- Trial name
- NCT00170625
- Testing
- Hycamtin
- Volunteers
- 28 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Ovarian Cancer
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
- Trial name
- NCT01851746
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wuhan University